A 9 year 3 month-old girl presented with at least 12 months of symptoms typical of hyperthyroidism. These included weight loss, weakness, tremors, irritability, sleeping difficulties, poor schookperformance, heat intolerance, palpitations, prominent eyes and rapid linear growth. She had a diffusely and markedly enlarged thyroid gland (Fig. 1) , evidence of mild exophthalmos, and was clinically thyrotoxic. She was prepubertal. Thyroid investigations: free thyroxine (T4) 68 pmol/1 (9.6-14.5), free triiodothyronine (T3) >46 pmol/1 (3.5-6.0), thyroid stimulating hormone (TSH) 0.03 mIU/1 (0.7-4.0), TSH receptor antibodies (TSHrAb) 95 IU/1
Fig. 2
A 9 year 3 month-old girl presented with at least 12 months of symptoms typical of hyperthyroidism. These included weight loss, weakness, tremors, irritability, sleeping difficulties, poor schookperformance, heat intolerance, palpitations, prominent eyes and rapid linear growth. She had a diffusely and markedly enlarged thyroid gland (Fig. 1) , evidence of mild exophthalmos, and was clinically thyrotoxic. She was prepubertal. Thyroid investigations: free thyroxine (T4) 68 pmol/1 (9.6-14.5), free triiodothyronine (T3) >46 pmol/1 (3.5-6.0), thyroid stimulating hormone (TSH) 0.03 mIU/1 (0.7-4.0), TSH receptor antibodies (TSHrAb) 95 IU/1 VOLUME 22, NO. 4,2009 IMAGES IN PEDIATRIC ENDOCRINOLOGY (<1.5). Graves' disease was diagnosed. Her height had increased from 124 cm (25 th percentile, height-SDS -0.67) to 144 cm (95* percentile, height-SDS +1.65) in the preceding 18 months ( Fig. 2 ; arrow indicates time of diagnosis and commencement of thionamide therapy). Her mid-parental height (MPH) was on the 90 th percentile (170 cm). Bone age (BA) was 10 years at chronological age (CA) 9 years 6 months. Hence her annualised growth velocity of 15 cm/year far exceeded the 97 percentile. Treatment with the thionamide, carbimazole, was commenced with achievement of euthyroid status after 2 months of therapy. Growth velocity reduced to 6.7 cm/year (75* percentile) and linear growth then continued to follow the 95* percentile. Bone ages measured at 6 and 12 months after diagnosis remained within normal limits compared to chronological age (BA 10 years 6 months at CA 9 years 11 months; BA 10 years 6 months at CA 10 years 6 months). The patient remained prepubertal.
Thyroid hormone receptors have been identified in chondrocytes and osteoblasts. T3 has direct effects on growth plates to stimulate chondrocyte proliferation/differentiation, mineralisation and angiogenesis. Thyroid hormones may also influence bone growth indirectly via maintenance of growth hormone gene expression and stimulation of insulin-like growth factor (IGF)-I and interleukins (IL-6, IL-8). Hence hyperthyroidism in childhood may cause accelerated linear growth. However, such growth acceleration has usually been associated with accelerated bone age.
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